Home

Site Map

About Us

Media Kit

Help

The leading web portal for pharmacy resources, news, education and careers

February 9, 2010

Pharmacy Choice - Pharmaceutical News - Mylan Inc awarded FDA approval for generic Prevacid DR Capsules - February 9, 2010

Pharmacy News Article

11/11/09 - Mylan Inc awarded FDA approval for generic Prevacid DR Capsules

Speciality pharmaceutical company Mylan Inc (Nasdaq:MYL) declared on Tuesday the receipt of final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed- release (DR) Capsules, 15 mg and 30 mg.

This FDA approval was secured by the company's privately held Indian subsidiary, Matrix Laboratories Ltd.

Lansoprazole DR Capsules will be shipped with immediate effect and will be sold under the Mylan Pharmaceuticals brand.

The company added Lansoprazole DR Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid DR Capsules. The brand product recorded US sales of approximately USD3bn for the 12 months ending 30 June, according to IMS Health.

((Comments on this story may be sent to tww.feedback@m2.com))